IMU-838 (30 mg/day)

Phase 2

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Relapsing-Remitting Multiple Sclerosis (RRMS)

Drug Information

Target Indication

Relapsing-Remitting Multiple Sclerosis (RRMS)

Clinical Trial

Last updated: 2/13/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

IMUX

IMMUNIC, INC.

Related Pipeline

Multiple Sclerosis, Relapsing-Remitting

Multiple Sclerosis